Total Funding
34
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
152772
Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer.
Acquired by 
Gilead Sciences
- David M. Goldenberg: Founder
Loretta Itri: Chief Medical OfficerPast Role: The Medicines, Executive Vice President
About the Company
Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company.
The company was founded in 1982 and headquartered in Morris Plains, New Jersey.
